BNT162b2 mRNA COVID-19 Vaccine Effectiveness in Patients with Coeliac Disease Autoimmunity: Real-World Data from Mass Vaccination Campaign
Viruses · 2023
DOI: 10.3390/v15091968 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Amir Ben-Tov und 7 weiteren Autor:innen. Beteiligte Einrichtung: Kahn Sagol Maccabi (KSM) Research and Innovation Center, Maccabi Healthcare Services, Tel Aviv 68125, Israel. Hauptthemen laut MEDLINE: Celiac Disease, COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Data on COVID-19 vaccine effectiveness among patients with coeliac disease are currently lacking because patients with immune conditions were excluded from clinical trials. We used our coeliac disease autoimmunity (CDA) cohort to explore the effectiveness of the BNT162b2 mRNA COVID-19 vaccine in preventing SARS-CoV-2 infection among patients with CDA.
Methods
This retrospective cohort study included patients with positive autoantibodies against tissue transglutaminase (tTG-IgA). In the primary analysis, the cohort included CDA patients who received two vaccine doses against COVID-19 and matched patients in a 1:3 ratio. Patients were divided into subgroups based on their positive tTG-IgA level at diagnosis and their current serology status.
Results
The cohort included 5381 vaccinated patients with CDA and 14,939 matched vaccinated patients. The risk for breakthrough SARS-CoV-2 infection evaluated with Kaplan–Meier survival analysis via log-rank tests was similar between groups (p = 0.71). In a Cox regression survival analysis, the hazard ratio for breakthrough infection among patients with CDA compared to matched patients was 0.91 (95% confidence interval = 0.77–1.09).
Conclusions
COVID-19 vaccination is effective in patients with coeliac disease autoimmunity. Vaccine effectiveness was comparable to the reference population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kahn Sagol Maccabi (KSM) Research and Innovation Center, Maccabi Healthcare Services, Tel Aviv 68125, Israel.
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 68125, Israel.
- Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA.
- Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, USA.
- Department of Gastroenterology, Tel Aviv Sourasky Medical Center, Tel Aviv 68125, Israel.
- The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Shaare Zedek Medical Center, The Hebrew University, Jerusalem 91905, Israel.
ORCID-Profile: Amir Ben-Tov, Gabriel Chodick, Amit Assa, Sivan Gazit, Tal Patalon
Zitieren
APA
Ben-Tov, A., Lebwohl, B., Banon, T., Chodick, G., Kariv, R., Assa, A., Gazit, S., & Patalon, T. (2023). BNT162b2 mRNA COVID-19 Vaccine Effectiveness in Patients with Coeliac Disease Autoimmunity: Real-World Data from Mass Vaccination Campaign. Viruses. https://doi.org/10.3390/v15091968
Vancouver
Ben-Tov A, Lebwohl B, Banon T, Chodick G, Kariv R, Assa A, et al. BNT162b2 mRNA COVID-19 Vaccine Effectiveness in Patients with Coeliac Disease Autoimmunity: Real-World Data from Mass Vaccination Campaign. Viruses. 2023. doi:10.3390/v15091968
BibTeX
@article{BenTov2023,
author = {Ben-Tov, Amir and Lebwohl, Benjamin and Banon, Tamar and Chodick, Gabriel and Kariv, Revital and Assa, Amit and Gazit, Sivan and Patalon, Tal},
title = {BNT162b2 mRNA COVID-19 Vaccine Effectiveness in Patients with Coeliac Disease Autoimmunity: Real-World Data from Mass Vaccination Campaign},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15091968}
}
EUVIMED